Impact of pharmacist intervention on osteoporosis treatment after fragility fracture: Positive effect of pharmacist information program shown in pilot study

Canadian Pharmaceutical Journal

Volumn 138, Issue 1, 2005, Pages 37-43

  Riley, Karen ^a,c   Martin, Janet ^a   Wazny, Lori D ^b  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b HEALTH SCIENCES CENTRE   (Canada)

^c Bluewater Health   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CORTICOSTEROID; ESTROGEN; ETIDRONIC ACID; RALOXIFENE; RISEDRONIC ACID; SALCATONIN; VITAMIN D;

ADULT; AGE; ALZHEIMER DISEASE; ANKLE FRACTURE; ARTICLE; BODY MASS; BONE DENSITOMETRY; CAUCASIAN; CLINICAL ARTICLE; COMMUNITY HOSPITAL; CONTROLLED STUDY; DEMENTIA; DUAL ENERGY X RAY ABSORPTIOMETRY; EARLY MENOPAUSE; ESTROGEN DEFICIENCY; FAMILY HISTORY; FEMALE; FOLLOW UP; FRAGILITY FRACTURE; GENERAL PRACTITIONER; HIP FRACTURE; HOSPITAL ADMISSION; HUMAN; MALE; NURSE; OSTEOPOROSIS; PATIENT EDUCATION; PHARMACIST; PILOT STUDY; PROPHYLAXIS; RISK FACTOR; SMOKING; WRIST FRACTURE;

EID: 26244456293     PISSN: 08286914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. About osteoporosis [online]. Toronto: Osteoporosis Society of Canada. Available: www.osteoporosis.ca/english/about%20osteoporosis/ default.asp?s=1 (accessed December 20, 2004.)
2. Hajcsar EE, Hawker G, Bogoch ER. Investigation and treatment of osteoporosis in patients with fragility fractures. CMAJ 2000;163:819-22.
3. Report of the Strategic Action Working Group on Osteoporosis. A Framework and Strategy for the Prevention and Management of Osteoporosis. Toronto: Ontario Women's Health Council funded by the Ontario Ministry of Health and Long-Term Care; 2000.
4. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285:785-95.
5. Fitt NS, Mitchell SL, Cranney A, et al. Influence of bone densitometry results on the treatment of osteoporosis. CMAJ 2001;164:777-81.
6. Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001;285:320-3.
7. Papaioannou A, Wiktorowicz M, Adachi J, et al. Mortality, independence in living, and re-fracture, one year following hip fracture in Canadians. J Soc Obstet Gynaecol Can 2000;22(8):591-7.
8. Osteoporosis and you [patient information brochure]. Toronto: Osteoporosis Society of Canada; 2000.
9. Ontario guidelines for the prevention and treatment of osteoporosis. Toronto: Ontario Program for Optimal Therapeutics; 2000.
10. Brown J, Josse R; Scientific Advisory Council of the Osteoporosis Society of Canada. 2002 Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002;167(10 Suppl):S1-34.
11. Scientific Advisory Board, Osteoporosis Society of Canada. Clinical practice guidelines for the diagnosis and management of osteoporosis. CMAJ 1996;155:1113-33.
12. Society of Obstetricians and Gynaecologists of Canada. Canadian Consensus Conference on Menopause and Osteoporosis. J Soc Obstet Gynaecol Can 1998;20(13-14):2-64.
13. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. N Engl J Med 1995;332(12):767-73.
14. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990;112:352-64.
15. American College of Rheumatology Task Force on Osteoporosis Guidelines. Recommendations for the prevention and treatment of glucocorticoid-induced Osteoporosis. Arthritis Rheum 1996;39:1791-801.
16. Buckley LM, Marquez M, Hudson JQ, et al. Variations in physicians' judgments about corticosteroid induced osteoporosis by physician specialty. J Rheumatol 1998;25:2195-202.
17. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with post-menopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-52.
18. Ensrud KE, Black DM, Palermo L, et al. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial. Arch Intern Med 1997;157:2617-24.
19. Beraducci A, Lengacher CA, Keller R. The impact of osteoporosis continuing education on nurses' knowledge and attitudes. J Contin Educ Nurs 2002;33:210-6.